Wegovy and Fertility: What the Evidence Currently Shows

What official guidance says about semaglutide and trying to conceive

The licensed prescribing information for Wegovy, reflected in NHS England's guidance on weight-management injections, is straightforward: semaglutide should be stopped before attempting to conceive. The standard recommendation is to stop treatment at least two months before trying, to allow the medicine to clear your system, semaglutide has a long half-life, and this wash-out period is clinically meaningful. During animal studies, exposures at doses higher than those used in humans were associated with adverse developmental outcomes. No comparable controlled human data exist, which is precisely why regulators default to caution rather than waiting for evidence of harm.

This is a question our prescribers hear most weeks, often from people who have made real progress on treatment and are now thinking about starting a family. The answer does not change with how long you have been on Wegovy or how well it has worked for you: the current evidence base does not support continuing semaglutide through conception or pregnancy. That conversation should happen with your GP or a specialist who knows your full history, not just your weight-loss prescriber.

If you become pregnant while taking Wegovy, stop the medicine and contact your maternity team promptly. Do not restart without specialist advice.

How weight loss itself may interact with fertility

Weight has a real, well-documented effect on reproductive hormones. Excess weight is associated with disrupted ovulation, irregular menstrual cycles, and conditions such as polycystic ovary syndrome (PCOS), all of which can make conception more difficult. Clinical evidence consistently shows that meaningful weight reduction (even 5–10% of body weight) can restore more regular ovulation in people with PCOS and improve hormonal profiles more broadly. The NICE recommendation for semaglutide (TA875) was made in part because of the wider health benefits that sustained weight loss produces, and reproductive health is part of that picture.

The practical implication is worth stating plainly: losing weight before trying to conceive (through any clinically supervised route) may improve your chances, not reduce them. Some people find that their cycles become more regular during treatment, which itself can increase the likelihood of an unintended pregnancy. Using reliable contraception while on Wegovy is therefore genuinely important, not a formality.

For a fuller look at how semaglutide interacts with fertility more broadly, including the emerging research across reproductive physiology, the dedicated page covers the evidence in more detail. The evidence on semaglutide and female fertility also covers the emerging research in more detail.

Contraception while taking Wegovy (a practical note

Wegovy can slow gastric emptying, particularly around dose changes, and this affects how quickly oral medicines) including the combined pill, are absorbed. NHS guidance specifically flags this for tirzepatide, but the same principle applies with any medicine that alters gut motility. The practical advice: if you rely on an oral contraceptive, discuss with your GP or sexual health clinic whether an additional method makes sense, particularly in the weeks following a dose increase.

Transdermal methods (patches, hormonal coils, implants) are unaffected by gastric transit and are often the more straightforward choice during GLP-1 treatment. This is not a decision to make alone; it belongs in a conversation with the clinician who manages your contraception. You can read more about Wegovy during pregnancy (including what to do if you conceive unexpectedly) in our dedicated guidance.

What remains uncertain, and who to speak to

Research into GLP-1 medicines and human fertility is active but still relatively early. Most of what is known comes from animal studies and observational data gathered while these treatments have been in widespread use, the kind of real-world signal that informs regulatory caution without yet drawing firm conclusions. The effect of semaglutide on sperm quality, ovarian reserve, or longer-term reproductive outcomes in humans is not yet established. If fertility is a central concern for you, a reproductive specialist is the right person to advise on timing, sequencing, and any investigations worth doing, not a weight-loss prescriber working in isolation.

For people without an imminent plan to conceive, Wegovy remains a clinically supported option for weight management where it is suitable, and its effects on the heart and cardiovascular health are among the most well-evidenced benefits covered in our dedicated guidance. The Wegovy treatment overview covers eligibility, the dosing schedule, and what to expect from treatment in full. If you are weighing up whether to start now or wait, that question is best answered in a consultation where your full medical history (including your fertility plans) can be considered properly.

If you are ready to explore whether treatment is right for your situation, check your eligibility through a free consultation reviewed the same day by a GPhC-registered prescriber. For questions about the male side of this topic, the evidence on semaglutide and male fertility is covered separately.